Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Monitoring Recommendations for Conventional DMARDs: Toxicities and Lab Surveillance
Description
The talk reviewed toxicity and monitoring for conventional DMARDs, focusing on methotrexate, azathioprine, and mycophenolate. Methotrexate commonly causes GI upset and can lead to myelosuppression, infection risk, pneumonitis, and liver injury. GI effects may improve with split dosing, subcutaneous administration, folic acid, or dose reduction. Bone marrow suppression risk is higher with renal dysfunction, older age, alcohol use, and interacting drugs such as trimethoprim-sulfamethoxazole, NSAIDs, and allopurinol. For liver monitoring, the speaker emphasized that methotrexate may worsen existing liver disease but is not clearly a direct cause of chronic fibrosis; baseline CBC, CMP, hepatitis B/C, TB screening, and pregnancy testing are recommended, with FIB-4 used to assess fibrosis risk and guide hepatology referral or secondary testing. During therapy, CBC and LFTs are checked monthly initially, then every three months if stable; mild LFT elevations under three times normal can usually be observed, while higher elevations warrant holding or reducing the drug. Azathioprine metabolism was explained in terms of TPMT, 6-TGN, and 6-MMP: low TPMT increases myelosuppression risk, high 6-TGN suggests dose reduction or alternative therapy, and high 6-MMP suggests hepatotoxicity and may warrant dose adjustment or allopurinol-assisted shunting. Baseline TPMT, and sometimes NUDT15 in East Asian patients, help guide dosing. Mycophenolate mofetil/mycophenolic acid commonly causes diarrhea and other GI symptoms, can cause cytopenias, infection risk, GU symptoms, and rarely PML; management includes dose adjustment, switching to enteric-coated formulations, close lab monitoring, and attention to drug interactions. Overall, the key message was that these drugs are effective but require individualized, structured lab surveillance to prevent serious toxicity.
View moreConclusions
- Methotrexate remains effective and generally safe, but it requires structured laboratory monitoring because myelosuppression, infection, and hepatotoxicity can occur.
- For methotrexate-related gastrointestinal intolerance, dose splitting, subcutaneous administration, folic acid, and dose reduction can improve tolerability.
- Methotrexate-associated liver enzyme elevations of less than three times the upper limit of normal can usually be managed by continuing treatment and rechecking labs soon rather than stopping immediately.
- Current evidence suggests methotrexate does not by itself cause chronic liver fibrosis, but it may worsen pre-existing metabolic or alcohol-related liver disease.
- FIB-4 is a practical tool for methotrexate liver-risk stratification, with high-risk patients needing methotrexate cessation and hepatology referral, and intermediate-risk patients needing continued treatment with noninvasive fibrosis assessment or specialist input.
- Patients starting methotrexate should have baseline CBC, CMP, hepatitis B and C screening, tuberculosis screening, pregnancy testing when relevant, and periodic CBC/LFT follow-up after initiation.
- In patients at higher risk for marrow suppression on methotrexate, a lower test dose and closer early monitoring are recommended.
- Azathioprine safety is strongly influenced by TPMT and, in some patients, NUDT15 status, so pre-treatment testing can help predict toxicity risk and guide dosing.
- Thiopurine metabolite testing can help distinguish underdosing, nonadherence, excessive active metabolite exposure, and preferential liver-toxic metabolite shunting during azathioprine therapy.
- Mycophenolate mofetil and mycophenolic acid are also effective csDMARDs, but GI intolerance, cytopenias, infection risk, and rare neurologic toxicity require ongoing monitoring and dose adjustment.
- Overall, conventional synthetic DMARDs can be used safely long term when baseline risk assessment, early lab surveillance, and drug-specific toxicity monitoring are applied consistently.
- Menter et al. JAAD, June 2020
- Di Martino V et al. Nat Rev Rheumatol. Feb 2023
- Kanwal et al. Hepatology. May 2024
- Zakerska-Banaszak et al. Toxics. 2022 10(4)
- Menter et al. JAAD. June 2020